Porphyrias

Lancet

Volumn 365, Issue 9455, 2005, Pages 241-252

  Kauppinen, Raili ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b BIOMEDICUM HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CHLORPROMAZINE; COPROPORPHYRINOGEN OXIDASE; DIAZEPAM; FERROCHELATASE; GABAPENTIN; GLUCOSE; HEME; LACTULOSE; LORAZEPAM; OPIATE; PORPHOBILINOGEN DEAMINASE; PORPHOBILINOGEN SYNTHASE; PORPHYRIN; PROTEIN PRECURSOR; PROTOPORPHYRINOGEN OXIDASE; SULFONAMIDE; UROPORPHYRINOGEN DECARBOXYLASE; VASOPRESSIN;

ABDOMINAL PAIN; ACUTE INTERMITTENT PORPHYRIA; AMINOLEVULINATE DEHYDRATASE DEFICIENCY PORPHYRIA; ANXIETY DISORDER; ARTIFICIAL VENTILATION; AUTONOMIC NEUROPATHY; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BABINSKI REFLEX; BLADDER SPHINCTER; BLOOD ANALYSIS; CHEMICAL ANALYSIS; CONFERENCE PAPER; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONSCIOUSNESS DISORDER; CONSTIPATION; CONVULSION; COPROPORPHYRIA; CRANIAL NEUROPATHY; DEPRESSION; DIAGNOSTIC ERROR; DIAPHRAGM PARALYSIS; DIARRHEA; DIET RESTRICTION; DYSARTHRIA; DYSPHAGIA; DYSPHONIA; ENZYME DEFICIENCY; ERYTHROPOIETIC PROTOPORPHYRIA; FACIAL NERVE PARALYSIS; FECES ANALYSIS; GLUCOSE INFUSION; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INSOMNIA; INTENSIVE CARE UNIT; LIMB PAIN; LIVER DISEASE; METABOLIC DISORDER; MOTOR NEUROPATHY; MUSCLE WEAKNESS; MUTATIONAL ANALYSIS; PATHOGENESIS; PHOTOSENSITIVITY; PHYSIOTHERAPY; PNEUMONIA; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; SENSORY NEUROPATHY; SPEECH THERAPY; STOMACH INTUBATION; SUNLIGHT PROTECTION; SYMPTOMATOLOGY; TACHYCARDIA; TREATMENT INDICATION; URINALYSIS; URINE CATHETER; VOMITING;

EID: 12344254822     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)70154-9     Document Type: Conference Paper

References (144)

1. Anderson KE, Sassa S, Bishop DF, Desnick RJ. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. Scriver CR, Beaudet A, Sly WS, Valle D. The metabolic and molecular bases of inherited disease. 8th edn:2001;2991-3062 McGraw-Hill, New York
2. Moore MR, McColl KE, Rimington C, Goldberg A. Disorders of porphyrin metabolism. 1987;Plenum Publishing Corporation, New York
3. Jordan PM, Dailey HI. Biochemistry of porphyrins. Mol Aspects Med. 11:1990;21-37
4. Bishop DF, Henderson AS, Astrin KH. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics. 7:1990;207-214
5. Fraser DJ, Podvinec M, Kaufmann MR, Meyer UA. Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem. 277:2002;34717-34726
6. Smith SJ, Cox TM. Translational control of erythroid delta- aminolevulinate synthase in immature human erythroid cells by heme. Cell Mol Biol. 43:1997;103-114
7. Christiansen L, Bygum A, Jensen A, et al. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet. 107:2000;612-614
8. Gouya L, Puy H, Robreau AM, et al. Modulation of penetrance by the wild-type allele in dominantly inherited erythropoieticprotoporphyria and acute hepatic porphyrias. Hum Genet. 114:2004;256-262
9. Brownlie P, Lambert R, Louie G, et al. The three-dimensional structures of mutants of porphobilinogen deaminase: toward an understanding of the structural basis of acute intermittent porphyria. Protein Sci. 3:1994;1644-1650
10. Al-Karadaghi S, Hansson M, Nikonov S, Jonsson B, Hederstedt L. Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis. Structure. 5:1997;1501-1510
11. Whitby FG, Phillips JD, Kushner JP, Hill CP. Crystal structure of human uroporphyrinogen decarboxylase. EMBO J. 17:1998;2463-2471
12. Mathews MA, Schubert HL, Whitby FG, et al. Crystal structure of human uroporphyrinogen III synthase. EMBO J. 20:2001;5832-5839
13. Koch M, Breithaupt C, Kiefersauer R, Freigang J, Huber R, Messerschmidt A. Crystal structure of protoporphyrinogen IX oxidase: a key enzyme in haem and chlorophyll biosynthesis. EMBO J. 23:2004;1720-1728
14. Christiansen L, Ged C, Hombrados I, et al. Screening for mutations in the uroporphyrinogen decarboxylase gene using denaturing gradient gel electrophoresis. Identification and characterization of six novel mutations associated with familial PCT. Hum Mutat. 14:1999;222-232
15. Mustajoki S, Laine M, Lahtela M, Mustajoki P, Peltonen L, Kauppinen R. Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen deaminase in COS-1 cells. Mol Med. 6:2000;670-679
16. Lamoril J, Puy H, Whatley SD, et al. Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. Am J Hum Genet. 68:2001;1130-1138
17. von und zu Fraunberg M, Timonen K, Mustajoki P, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet. 10:2002;649-657
18. Shady AA, Colby BR, Cunha LF, Astrin KH, Bishop DF, Desnick RJ. Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene. Br J Haematol. 117:2002;980-987
19. Whatley SD, Puy H, Morgan RR, et al. Variegate porphyria in western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet. 65:1999;984-994
20. Andersson C, Floderus Y, Wikberg A, Lithner F. The W198X and R173W mutations in the porphobilinogen deaminase gene in acute intermittent porphyria have higher clinical penetrance than R167W: a population-based study. Scand J Clin Lab Invest. 60:2000;643-648
21. Minder EI, Gouya L, Schneider-Yin X, Deybach JC. A genotype-phenotype correlation between null-allele mutations in the ferrochelatase gene and liver complication in patients with erythropoietic protoporphyria. Cell Mol Biol. 48:2002;91-96
22. Wiman A, Floderus Y, Harper P. Novel mutations and phenotypic effect of the splice site modulator IVS3-48C in nine Swedish families with erythropoietic protoporphyria. J Hum Genet. 48:2003;70-76
23. von und zu Fraunberg M, Pischik E, Udd L, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine (Baltimore). 84:2005;35-47
24. Whatley SD, Roberts AG, Llewellyn DH, Bennett CP, Garrett C, Elder GH. Non-erythroid form of acute intermittent porphyria caused by promoter and frameshift mutations distant from the coding sequence of exon 1 of the HMBS gene. Hum Genet. 107:2000;243-248
25. Bulaj ZJ, Phillips JD, Ajioka RS, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood. 95:2000;1565-1571
26. Hift RJ, Meissner D, Meissner PN. A systematic study of the clinical and biochemical expression of variegate porphyria in a large South African family. Br J Dermatol. 151:2004;465-471
27. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 18:1998;43-52
28. Schneider-Yin X, Gouya L, Meier-Weinand A, Deybach JC, Minder EI. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr. 159:2000;719-725
29. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med. 153:1993;2004-2008
30. Crimlisk HL. The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psych. 62:1997;319-328
31. Murphy GM. The cutaneous porphyrias: a review. Br J Dermatol. 140:1999;573-581
32. Hindmarsh JT, Oliveras L, Greenway DC. Biochemical differentiation of the porphyrias. Clin Biochem. 32:1999;609-619
33. de Rooij WM, Edixhoven A, Wilson JH. Porphyria: a diagnostic approach. Kadish KM, Smith KM, Guilard R. The porphyrin handbook. 2003;211-245 Elsevier, St Louis
34. Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem. 48:2002;1891-1900
35. Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones - a population-based study in northern Sweden. J Intern Med. 254:2003;176-183
36. Pischik E, Bulyanitsa A, Kazakov V, Kauppinen R. Clinical features predictive of a poor prognosis in acute porphyria. J Neurol (in press).
37. Ridley A, Hierons R, Cavanagh JB. Tachycardia and the neuropathy of porphyria. Lancet. 2:1968;708-710
38. Jensen MP, Karoly P. Self-report scales and procedures for assessing pain in adults. Turk DC, Melzack R. Handbook of pain assessment. 1992;135-151 Guildford Press, New York
39. Dichter HN, Taddeini L, Lin S, Ayala GF. Delta amino levulinic acid: effect of a porphyrin precursor on an isolated neuronal preparation. Brain Res. 126:1977;189-195
40. Sima AA, Kennedy JC, Blakeslee D, Robertson DM. Experimental porphyric neuropathy: a preliminary report. Can J Neurol Sci. 8:1981;105-113
41. Kauppinen R. Molecular diagnostics of acute intermittent porphyria. Expert Rev Mol Diagn. 4:2004;243-249
42. Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet. 363:2004;705-706
43. Bradbury M. The concept of a blood-brain barrier. 1979;John Wiley and Sons, Chichester
44. Yen PS, Chen CJ, Lui CC, Wai YY, Wan YL. Diffusion-weighted magnetic resonance imaging of porphyric encephalopathy: a case report. Eur Neurol. 48:2002;119-121
45. Andersson C, Thunell S, Floderus Y, et al. Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of mutation analysis and biochemical methods. J Intern Med. 237:1995;301-308
46. Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis. 18:1998;57-65
47. Lim CK, Peters TJ. Urine and fecal profiles by reverse-phase high performance liquid chromatograqphy in the porphyrias. Clin Chem Acta. 139:1984;55-63
48. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine. 71:1992;1-13
49. Doss MO, Stauch T, Gross U, et al. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis. 27:2004;529-536
50. Tandon SK, Chatterjee M, Bhargava A, Shukla V, Bihari V. Lead poisoning in Indian silver refiners. Sci Total Environ. 281:2001;177-182
51. Schoenfeld N, Mamet R, Dotan I, Sztern M, Levo Y, Aderka D. Relation between uroporphyrin excretion, acute attacks of hereditary coproporphyria and successful treatment with haem arginate. Clin Sci. 88:1995;365-369
52. Kuhnel A, Gross U, Doss MO. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem. 33:2000;465-473
53. Elder GH, Worwood M. Mutations in the hemochromatosis gene, porphyria cutanea tarda, and iron overload. Hepatology. 27:1998;289-291
54. Hift RJ, Davidson BP, van der Hooft C, Meissner DM, Meissner PN. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem. 50:2004;915-923
55. Poh-Fitzpatrick MB, Lamola AA. Direct spectrofluorometry of diluted erythrocytes and plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med. 87:1976;362-370
56. Mustajoki P, Tenhunen R, Pierach C, Volin L. Heme in the treatment of porphyrias and hematological disorders. Semin Hematol. 26:1989;1-9
57. Grandchamp B, Picat C, Mignotte V, et al. Tissue-specific splicing mutation in acute intermittent porphyria. Proc Natl Acad Sci USA. 86:1989;661-664
58. Daimon M, Susa, Igarashi M, Kato T, Kameda W. Administration of heme arginate, but not hematin, caused anaphylactic shock. Am J Med. 110:2001;240
59. Green D, Ts'ao CH. Hematin: effects on hemostasis. J Lab Clin Med. 115:1990;144-147
60. Thunell S, Bjernevik K, Thunnel G. Patient's and doctor's guide to medication in the acute porphyrias 1999-2000. 2000;54 Porphyria Centre Sweden, Stockholm
61. Gorchein A. Treatment of Parkinson's disease in a patient with acute intermittent porphyria. Br J Clin Pharmacol. 40:1995;105-106
62. Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol. 44:1997;427-434
63. Zadra M, Grandi R, Erli LC, Mirabile D, Brambilla A. Treatment of seizures in acute intermittent porphyria: safety and efficacy of gabapentin. Seizure. 7:1998;415-416
64. Holroyd S, Seward RL. Psychotropic drugs in acute intermittent porphyria. Clin Pharmacol Ther. 66:1999;323-325
65. Forget F, Awada A, Klastersky J. Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria: a case report and review of the literature. Support Care Cancer. 9:2001;465-466
66. Doss MO, Kuhnel A, Gros U. Alcohol and porphyrin metabolism. Alcohol Alcohol. 35:2000;109-125
67. Thunell S, Floderus Y, Henrichson A, Moore MR, Meissner P, Sinclair J. Alcoholic beverages in acute porphyria. J Stud Alcohol. 53:1992;272-276
68. Anderson KE, Spitz IM, Bardin CW, Kappas A. A gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med. 150:1990;1469-1474
69. Gross U, Honcamp M, Daume E, Frank M, Dusterberg B, Doss MO. Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Horm Metab Res. 27:1995;379-383
70. Jeans JB, Savik K, Gross CR, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet. 65:1996;269-273
71. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer. 57:1988;117-120
72. Andersson C, Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med. 236:1994;169-175
73. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med. 240:1996;195-201
74. Andant C, Puy H, Deybach JC, Soule JC, Nordmann Y. Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria. Am J Gastroenterol. 92:1997;1389-1390
75. Laiwah AA, Mactier R, McColl KE, Moore MR, Goldberg A. Early-onset chronic renal failure as a complication of acute intermittent porphyria. Q J Med. 52:1983;92-98
76. Linet MS, Gridley G, Nyren O, et al. Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden. Am J Epidemiol. 149:1999;1010-1015
77. Aggarwal N, Bagga R, Sawhney H, Suri V, Vasishta K. Pregnancy with acute intermittent porphyria: a case report and review of literature. J Obstet Gynaecol Res. 28:2002;160-162
78. Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatol. 3:1986;148-157
79. Poh-Fitzpatrick MB. Porphyrias: photosensitivity and phototherapy. Methods Enzymol. 319:2000;485-493
80. Timonen K, Niemi KM, Mustajoki P, Tenhunen R. Skin changes in variegate porphyria: clinical, histopathological, and ultrastructural study. Arch Dermatol Res. 282:1990;108-114
81. Timonen K, Niemi KM, Mustajoki P. Skin morphology in porphyria cutanea tarda does not improve despite clinical remission. Clin Exp Dermatol. 16:1991;355-358
82. Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol. 19:1992;40-47
83. Herrmann G, Wlaschek M, Bolsen K, Prenzel K, Goerz G, Scharffetter-Kochanek K. Photosensitization of uroporphyrin augments the ultraviolet A-induced synthesis of matrix metalloproteinases in human dermal fibroblasts. J Invest Dermatol. 107:1996;398-403
84. Sarkany RP. The management of porphyria cutanea tarda. Clin Exp Dermatol. 26:2001;225-232
85. Kirsch RE, Meissner PN, Hift RJ. Variegate porphyria. Semin Liver Dis. 18:1998;33-41
86. Brodie MJ, Thompson GG, Moore MR, Beattie AD, Goldberg A. Hereditary coproporphyria: demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med. 46:1977;229-241
87. Dabrowska E, Jablonska-Kaszewska I, Bielawski KP, Falkiewicz B. Influence of hepatitis C virus (HCV) infection on porphyrin and iron metabolism in porphyria cutanea tarda (PCT) patients. Med Sci Monit. 7:2001;190-196
88. Cruz-Rojo J, Fontanellas A, Moran-Jimenez MJ, et al. Precipitating/ aggravating factors of porphyria cutanea tarda in Spanish patients. Cell Mol Biol. 48:2002;845-852
89. Lamoril J, Andant C, Gouya L, et al. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol. 48:2002;33-41
90. Gisbert JP, Garcia-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol. 39:2003;620-627
91. Gardlo K, Selimovic D, Bolsen K, Ruzicka T, Abel J, Fritsch C. Cytochrome p450A1 polymorphisms in a Caucasian population with porphyria cutanea tarda. Exp Dermatol. 12:2003;843-848
92. Albalate M, Farinas MC, Octavio JG, Perez JH, Goicoechea M, Caramelo C. Development of porphyria cutanea tarda in a hemodialysis patient after reactivation of hepatitis C virus infection. Nephron. 88:2001;170-173
93. Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol. 42:2000;645-652
94. Gisbert JP, Garcia-Buey L, Alonso A, et al. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol. 16:2004;689-692
95. Siersema PD, ten Kate FJ, Mulder PG, Wilson JH. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver. 12:1992;56-61
96. Ma Y, Fracanzani AL, Sampietro M, et al. Autoantibodies to human cytosol: a marker of sporadic porphyria cutanea tarda. Clin Exp Immunol. 126:2001;47-53
97. Gocmen A, Peters HA, Cripps DJ, Bryan GT, Morris CR. Hexachlorobenzene episode in Turkey. Biomed Environ Sci. 2:1989;36-43
98. Hindmarsh JT, Oliveras L, Greenway DC. Plasma porphyrins in the porphyrias. Clin Chem. 45:1999;1070-1076
99. Elder GH, Lee GB, Tovey JA. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med. 299:1978;274-278
100. Kushner JP, Barbuto AJ, Lee GR. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J Clin Invest. 58:1976;1089-1097
101. Lecha M, Herrero C, Ozalla D. Diagnosis and treatment of the hepatic porphyrias. Dermatol Ther. 16:2003;65-72
102. Egger NG, Goeger DE, Anderson KE. Effects of chloroquine in hematoporphyrin-treated animals. Chem Biol Interact. 102:1996;69-78
103. Solis JA, Betancor P, Campos R, et al. Association of porphyria cutanea tarda and primary liver cancer: report of ten cases. J Dermatol. 9:1982;131-137
104. Murphy GM. Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther. 16:2003;57-64
105. Todd DJ. Erythropoietic protoporphyria. Br J Dermatol. 131:1994;751-766
106. Timonen K, Kariniemi AL, Niemi KM, Teppo AM, Tenhunen R, Kauppinen R. Vascular changes in erythropoietic protoporphyria: histopathologic and immunohistochemical study. J Am Acad Dermatol. 43:2000;489-497
107. Mathews-Roth MM, Wise RJ, Miller BA. Burst-forming units-erythroid from erythropoietic protoporphyria patients fluoresce under 405 nm light. Blood. 87:1996;4480-4481
108. Desnick RJ, Astrin KH. Congenital erythropoietic porphyria: advances in pathogenesis and treatment. Br J Haematol. 117:2002;779-795
109. Freesemann AG, Bhutani LK, Jacob K, Doss MO. Interdependence between degree of porphyrin excess and disease severity in congenital erythropoietic porphyria (Gunther's disease). Arch Dermatol Res. 289:1997;272-276
110. Cox TM. Erythropoietic protoporphyria. J Inherit Metab Dis. 20:1997;258-269
111. Pasanen AV, Salmi M, Vuopio P, Tenhunen R. Heme biosynthesis in sideroblastic anemia. Int J Biochem. 12:1980;969-974
112. Warren LJ, George S. Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB phototherapy. Australas J Dermatol. 39:1998;179-182
113. Murphy GM. Diseases associated with photosensitivity. J Photochem Photobiol B. 64:2001;93-98
114. Meerman L, Haagsma EB, Gouw AS, Slooff MJ, Jansen PL. Long-term follow-up after liver transplantation for erythropoietic protoporphyria. Eur J Gastroenterol Hepatol. 11:1999;431-438
115. Chen FP, Risheg H, Liu Y, Bloomer J. Ferrochelatase gene mutations in erythropoietic protoporphyria: focus on liver disease. Cell Mol Biol. 48:2002;83-89
116. Harada FA, Shwayder TA, Desnick RJ, Lim HW. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol. 45:2001;279-282
117. Fritsch C, Lang K, Bolsen K, Lehmann P, Ruzicka T. Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol. 11:1998;347-357
118. Shaw PH, Mancini AJ, McConnell JP, Brown D, Kletzel M. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant. 27:2001;101-105
119. Doss M, Schneider J, von Tiepermann R, Brandt A. New type of acute porphyria with porphobilinogen synthase (delta-aminolevulinic acid dehydratase) defect in the homozygous state. Clin Biochem. 15:1982;52-55
120. Gross U, Sassa S, Jacob K, et al. 5-aminolevulinic acid dehydratase deficiency porphyria: a twenty-year clinical and biochemical follow-up. Clin Chem. 44:1998;1892-1896
121. Thunell S, Henrichson A, Floderus Y, et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem. 30:1992;599-606
122. Beukeveld GJ, Wolthers BG, Nordmann Y, Deybach JC, Grandchamp B, Wadman SK. A retrospective study of a patient with homozygous form of acute intermittent porphyria. J Inherit Metab Dis. 13:1990;673-683
123. Llewellyn DH, Smyth SJ, Elder GH, Hutchesson AC, Rattenbury JM, Smith MF. Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene. Hum Genet. 89:1992;97-98
124. Frank J, McGrath J, Lam H, Graham RM, Hawk JL, Christiano AM. Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J Invest Dermatol. 110:1998;452-455
125. Roberts AG, Puy H, Dailey TA, et al. Molecular characterization of homozygous variegate porphyria. Hum Mol Genet. 7:1998;1921-1925
126. Kauppinen R, Timonen K, von und zu Fraunberg M, et al. Homozygous variegate porphyria: 20 years' follow up and characterization of molecular defect. J Invest Dermatol. 116:2001;610-613
127. Elder GH, Roberts AG. Uroporphyrinogen decarboxylase. J Bioenerg Biomembr. 27:1995;207-214
128. Mendez M, Rossetti MV, De Siervi A, del Carmen Batlle AM, Parera V. Mutations in familial porphyria cutanea tarda: two novel and two previously described for hepatoerythropoietic porphyria. Hum Mutat. 16:2000;269-270
129. Halapi E, Hakonarson H. Advances in the development of genetic markers for the diagnosis of disease and drug response. Expert Rev Mol Diagn. 2:2002;411-421
130. Lindberg RL, Porcher C, Grandchamp B, et al. Porphobilinogen deaminase deficiency in mice cause a neuropathy resembling that human hepatic porphyria. Nat Genet. 12:1996;195-199
131. Medlock AE, Meissner PN, Davidson BP, Corrigall AV, Dailey HA. A mouse model for South African (R59W) variegate porphyria: construction and initial characterization. Cell Mol Biol. 48:2002;71-78
132. Meerman L, Koopen NR, Bloks V, et al. Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria. Gastroenterology. 117:1999;696-705
133. Phillips JD, Jackson LK, Bunting M, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci USA. 98:2001;259-264
134. Fontanellas A, Mendez M, Mazurier F, et al. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Gene Ther. 8:2001;618-626
135. Johansson A, Moller C, Fogh J, Harper P. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement. Mol Med. 9:2003;193-199
136. Pawliuk R, Bachelot T, Wise RJ, Mathews-Roth MM, Leboulch P. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med. 5:1999;768-773
137. Richard E, Mendez M, Mazurier F, et al. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther. 4:2001;331-338
138. Richard E, Geronimi F, Lalanne M, et al. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J Gene Med. 5:2003;737-747
139. Geronimi F, Richard E, Lamrissi-Garcia I, et al. Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells. J Mol Med. 81:2003;310-320
140. Johansson A, Nowak G, Moller C, Blomberg P, Harper P. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria. Mol Ther. 10:2004;337-343
141. Johansson A, Moller C, Harper P. Correction of the biochemical defect in porphobilinogen deaminase deficient cells by non-viral gene delivery. Mol Cell Biochem. 250:2003;65-71
142. Johansson A, Nowak G, Moller C, Harper P. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria. Mol Genet Metab. 82:2004;20-26
143. Johansson A, Moller C, Gellerfors P, Harper P. Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells. Scand J Clin Lab Invest. 62:2002;105-113
144. Tarner IH, Muller-Ladner U, Fathman CG. Targeted gene therapy: frontiers in the development of 'smart drugs'. Trends Biotechnol. 22:2004;304-310